Patents Assigned to M Bio Technology Inc.
-
Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of
Patent number: 10870669Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.Type: GrantFiled: December 27, 2018Date of Patent: December 22, 2020Assignee: M BIO TECHNOLOGY INC.Inventors: Kazuhiro Matsuda, Yuko Shingu -
Publication number: 20190161512Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.Type: ApplicationFiled: December 27, 2018Publication date: May 30, 2019Applicant: M BIO TECHNOLOGY INC.Inventors: Kazuhiro MATSUDA, Yuko SHINGU
-
Patent number: 10232026Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.Type: GrantFiled: December 13, 2016Date of Patent: March 19, 2019Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
-
Publication number: 20170165343Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.Type: ApplicationFiled: December 13, 2016Publication date: June 15, 2017Applicants: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
-
Patent number: 9539209Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.Type: GrantFiled: June 4, 2010Date of Patent: January 10, 2017Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
-
Publication number: 20130217031Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.Type: ApplicationFiled: December 28, 2012Publication date: August 22, 2013Applicant: M BIO TECHNOLOGY INC.Inventor: M BIO TECHNOLOGY INC.
-
Patent number: 8367076Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.Type: GrantFiled: June 13, 2007Date of Patent: February 5, 2013Assignee: M Bio Technology Inc.Inventors: Kazuhiro Matsuda, Yuko Shingu
-
Publication number: 20120135067Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.Type: ApplicationFiled: June 4, 2010Publication date: May 31, 2012Applicants: M BIO TECHNOLOGY INC., NATIONAL INSTITUTE OF INFECTIOUS DISEASESInventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura